Vertical: CNMBase Year: 2025
Market Size (2025)
$820.22M
Projected (2032)
$1.60B
CAGR (2022–2032)
10.1%
Key Players
13+
The global microbial biostimulants market was valued at US$ 820.2 Mn in 2025 and is projected to reach US$ 1,603.5 Mn by 2032, growing at a CAGR of 10.0% over 2026–2032. The market has expanded from US$ 613.0 Mn in 2022 and is expected to cross US$ 1,000 Mn in 2028, when it is projected to reach US$ 1,095.0 Mn.
Microbial biostimulants are formulations of live bacteria or fungi applied to seeds, soil or foliage to improve nutrient uptake and nutrient use efficiency, tolerance to abiotic stress, and crop quality, independently of the product's own nutrient content. Demand is supported by efforts to improve fertilizer efficiency, the build-out of dedicated regulatory categories in major markets, and continued investment by crop input companies in biological portfolios.
Key Findings
Market size: US$ 820.2 Mn in 2025, rising to US$ 903.4 Mn in 2026 and US$ 1,603.5 Mn in 2032 (CAGR 10.0%, 2026–2032).
Microorganism type: Bacterial products accounted for 60.0% of the market in 2025. Fungal products are projected to grow faster, at a CAGR of 11.1%, raising their share to 42.8% by 2032.
Crop type: Fruits & Vegetables was the largest crop segment in 2025 (45.0%) and is projected to be the fastest growing, at a CAGR of 10.9%.
Application method: Seed Treatment and Soil application each held 40.0% of the market in 2025. Seed Treatment is projected to grow at a CAGR of 11.6% and become the leading method, with a 44.2% share by 2032.
Region: Europe was the largest regional market in 2025 (37.0% share). Middle East & Africa (12.5%) and Asia Pacific (12.1%) are projected to record the highest CAGRs over 2026–2032.
Countries: The U.S. was the largest country market in 2025 at US$ 128.0 Mn. India is projected to be the fastest-growing country market, at a CAGR of 14.1%.
The Microbial Biostimulants Market market is projected to grow at a CAGR of 10.1% from 2022 to 2032.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansMarket Definition
Plant biostimulants are products that stimulate natural plant processes independently of their nutrient content, with the aim of improving one or more of the following: nutrient use efficiency, tolerance to abiotic stress, crop quality traits, and the availability of nutrients confined in the soil or rhizosphere. Microbial biostimulants are the subset of these products whose active component is one or more live microorganisms.
For the purpose of this study, the microbial biostimulants market covers products based on beneficial bacteria (for example, species of Bacillus, Pseudomonas, Azospirillum, Azotobacter and Rhizobium) and beneficial fungi (for example, arbuscular mycorrhizal fungi and Trichoderma species) that are marketed for plant growth, nutrient use efficiency or stress tolerance. Microbial products sold primarily for the control of pests and diseases (biopesticides) are outside the scope of this study.
Scope of the Study
The market is analyzed by microorganism type, crop type, application method and region, with country-level analysis for the major markets in each region. Market values are presented in US$ Million for each year from 2022 to 2032.
Research Methodology
The market estimates in this report are based on a combination of secondary and primary research. Secondary research covered company annual reports and investor presentations, product registration databases, government and regulatory publications, trade association material, scientific literature and industry news. Primary inputs were used to validate adoption levels, pricing and segment splits.
Market size was estimated using both top-down and bottom-up approaches. The top-down approach started from the broader plant biostimulants and agricultural biologicals markets and applied the share attributable to microbial products. The bottom-up approach built up demand by region and country from crop area, adoption rates and application economics. The results were triangulated to arrive at the final estimates. Segment and country splits were derived for the base year 2025 and projected over the forecast period based on the drivers, restraints and trends described in this report.
Base year: 2025. Values for 2022–2024 are historical; values for 2026–2032 are forecasts.
Growth rates: CAGR figures refer to the period 2026–2032.
Currency: All values are in US$ Million at nominal prices.
Rounding: Values are rounded to one decimal place; totals may differ slightly from the sum of components.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansThe market estimates in this report are based on a combination of secondary and primary research. Secondary research covered company annual reports and investor presentations, product registration databases, government and regulatory publications, trade association material, scientific literature and industry news. Primary inputs were used to validate adoption levels, pricing and segment splits.
Market size was estimated using both top-down and bottom-up approaches. The top-down approach started from the broader plant biostimulants and agricultural biologicals markets and applied the share attributable to microbial products. The bottom-up approach built up demand by region and country from crop area, adoption rates and application economics. The results were triangulated to arrive at the final estimates. Segment and country splits were derived for the base year 2025 and projected over the forecast period based on the drivers, restraints and trends described in this report.
Base year: 2025. Values for 2022–2024 are historical; values for 2026–2032 are forecasts.
Growth rates: CAGR figures refer to the period 2026–2032.
Currency: All values are in US$ Million at nominal prices.
Rounding: Values are rounded to one decimal place; totals may differ slightly from the sum of components.
Base Year
2025
Historical Period
2022 – 2024
Forecast Period
2026 – 2032
Primary Interviews
150+
Historical data (2022–2025) and forecast period (2025–2032)
Our research process spans primary interviews with industry stakeholders combined with comprehensive secondary data analysis, validated through triangulation across multiple independent sources.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansMarket Structure
The microbial biostimulants market is fragmented. It includes multinational crop input companies that have built biological portfolios through acquisitions and partnerships, specialist biological companies with proprietary strain collections and fermentation capabilities, and a large number of regional and local producers, particularly in Asia Pacific and Latin America.
Competition is based on strain performance and the supporting trial data, product quality and shelf life, regulatory approvals in each market, access to distribution and agronomic support. Large companies use their seed, crop protection and fertilizer channels to reach growers, while specialist firms often compete through partnerships and distribution agreements.
Key Market Participants
Leading companies active in the microbial biostimulants market include the following:
Key Strategies
Acquisitions: Crop input companies and private equity-backed platforms are acquiring specialist biological companies to gain strains, products, manufacturing capacity and market access.
Partnerships and distribution agreements: Developers partner with distributors, cooperatives and seed companies to reach growers, while larger companies license or co-develop strains with start-ups.
Manufacturing investment: New fermentation and formulation capacity supports scale-up and supply security.
Regulatory positioning: Companies are building efficacy dossiers to secure approvals under the EU, Indian, Chinese and Brazilian frameworks, where registration requirements are becoming stricter.
Threat of new entrants: Moderate; Entry barriers include strain intellectual property, fermentation scale-up, efficacy data and registration costs. Start-ups and regional producers continue to enter, particularly in emerging markets.
Bargaining power of suppliers: Low to Moderate; Fermentation media, carriers and packaging are widely available. Proprietary strains and contract fermentation capacity give some suppliers greater leverage.
Bargaining power of buyers: Moderate; Large distributors and grower groups can negotiate on price, and growers can switch products between seasons. Agronomic support and demonstrated results reduce switching.
Threat of substitutes: Moderate; Non-microbial biostimulants (seaweed extracts, humic substances, protein hydrolysates) and conventional fertilizers are substitutes, though they are often used alongside microbial products.
Competitive rivalry: High; The market includes multinational crop input companies, specialist biological firms and many regional producers, with active consolidation and product launches.
Market estimates by geography (2032)
InsightEurope leads with $514.71M by 2032, while Middle East & Africa is projected to grow fastest at a 12.5% CAGR.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription Plans| REGION | 2022 | 2025 | 2032 | CAGR | SHARE |
|---|---|---|---|---|---|
| North America | $124.43M | $196.56M | $307.23M | 9.5% | 19% |
| Europe | $237.83M | $354.13M | $514.71M | 8.0% | 32% |
| Asia Pacific | $127.50M | $227.80M | $403.27M | 12.2% | 25% |
| Latin America | $94.40M | $164.13M | $284.62M | 11.7% | 18% |
| Middle East & Africa | $28.81M | $52.12M | $93.64M | 12.5% | 6% |
| Total | $612.96M | $994.74M | $1.60B | 10.1% | 100% |
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansTotal Market Size
$1.60B
| APPLICATION | REVENUE ($B) | GROWTH RATE | MARKET PENETRATION |
|---|---|---|---|
| Bacterial | $917.19M | 9.4% | 57% |
| Fungal | $686.29M | 11.2% | 43% |
* Revenue projections based on 2025 estimates. Growth rates represent CAGR 2024–2030. Market penetration indicates current adoption rate within addressable market segments.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSee plans for professionals or small and medium businesses.
Analytical insights on Microbial Biostimulants Market covering market dynamics, competitive landscape, and strategic outlook.
The Microbial Biostimulants Market market is projected to reach $1.60B by 2032, growing at 10.1% CAGR. The Bacterial segment holds the largest share.
Focus on nutrient use efficiency: Volatile fertilizer prices, particularly the price increases of 2021–2022, and concern over nutrient losses to water and air have increased interest in products that help crops capture more of the applied and residual nutrients. In the European Union, the Farm to Fork Strategy set targets to reduce nutrient losses by at least 50% and fertilizer use by at least 20% by 2030.
Dedicated regulatory categories: The EU Fertilising Products Regulation (EU) 2019/1009, applicable since July 2022, created a harmonized category for CE-marked microbial plant biostimulants, giving qualifying products access to the whole EU market. India brought biostimulants under the Fertilizer (Control) Order in 2021, and Brazil enacted a dedicated bioinputs law in December 2024.
Abiotic stress and climate variability: More frequent drought, heat and salinity stress has increased demand for inputs that support crop performance under stress, a claim category specifically recognized for biostimulants.
Investment by crop input companies: Large agricultural input companies have built biological portfolios through acquisitions, partnerships and new manufacturing capacity, widening distribution reach and grower access.
Sustainability programs: Food companies, retailers and grower programs focused on soil health, residue reduction and lower-input production create pull-through demand, especially in fruit and vegetable supply chains.
Expansion of permitted microorganisms in the EU: The European Commission is developing a methodology to add microorganisms to the CE-marked microbial biostimulant category. The methodology is expected to be finalized in 2026, with the first additions expected in 2027.
Nitrogen-fixing products for row crops: Microbial products that supply part of the nitrogen requirement of corn and other cereals have reached commercial scale in the U.S., opening a large addressable area beyond legume inoculants.
Seed treatment integration: Partnerships with seed companies and treaters allow microbial products to reach growers on pre-treated seed, reducing handling requirements on the farm.
High-growth emerging markets: Asia Pacific, Latin America and Middle East & Africa are projected to grow faster than the global average over 2026–2032, supported by large crop areas, export horticulture and evolving regulation.
Combination products: Formulations that combine microorganisms with non-microbial biostimulants or nutrients offer more consistent performance and simpler use.
Variable field performance: Results depend on soil type, climate, crop, native soil microbiology and management. Inconsistent responses across sites and seasons limit grower confidence and slow repeat purchases.
Shelf life and handling: Products contain live organisms, so viability can decline during storage, transport and application, particularly under high temperatures. Compatibility with seed treatments and tank-mix partners must also be managed.
Regulatory fragmentation: Definitions and registration requirements differ between countries. The EU harmonized category currently admits only four groups of microorganisms, the U.S. has no federal definition of a plant biostimulant, and India cancelled all provisional biostimulant registrations in June 2025.
Awareness and cost among smallholders: In many developing markets, limited extension support and price sensitivity restrict adoption beyond high-value crops and progressive growers.
Substantiating claims: Under the EU framework, efficacy claims must be demonstrated, and harmonized test methods for plant biostimulants are being developed by the European Committee for Standardization (CEN/TC 455). Generating multi-site, multi-season trial data increases development cost and time to market.
Product quality: Products with low or incorrect microbial counts undermine confidence in the category. The registration clean-up in India and stricter field-trial requirements in China reflect regulators' efforts to address this.
On-farm production and intellectual property: In Brazil, the 2024 bioinputs law permits farmers to produce bioinputs for their own use, which may compete with commercial products and raises questions about the protection of proprietary strains.
Consolidation: Acquisitions of specialist biological companies by larger crop input companies and private equity-backed platforms continued through 2023–2026.
Shift toward consortia: Product development is moving from single strains to multi-strain and multi-function consortia designed for more consistent results across environments.
Formulation advances: Investment in fermentation, encapsulation and stabilization technologies aims to extend shelf life and improve on-seed survival.
Distribution partnerships: Biological developers increasingly partner with established distributors and cooperatives to reach growers, as in the 2026 agreement under which Rovensa Next will commercialize Novonesis plant health biosolutions in the U.S. from the 2027 season.
Growth of seed-applied products: Seed Treatment is the fastest-growing application method globally, projected to grow at a CAGR of 11.6% over 2026–2032.
The microbial biostimulants value chain comprises five main stages:
Strain discovery and R&D: Isolation, screening and characterization of strains, supported by genomics and greenhouse and field trials. Large companies combine internal research with partnerships with start-ups, universities and strain libraries.
Fermentation and production: Bacteria are typically produced by liquid or solid-state fermentation; mycorrhizal fungi, being obligate symbionts, require host-based or specialized culture systems, which raises production cost.
Formulation and quality control: Strains are formulated into liquids, powders, granules or seed-applied products, with controls on viable counts, purity and shelf life.
Registration and commercialization: Products are registered under national or regional fertilizer, biostimulant or bioinput frameworks, often requiring multi-location efficacy data.
Distribution and end use: Products reach growers through distributors, agricultural retailers, cooperatives and seed companies, with agronomic support playing an important role in adoption.
Mar 2023: Corteva Agriscience; Completed the acquisitions of Stoller and Symborg, forming the Corteva Biologicals portfolio, which includes the nitrogen-fixing bacterial product Utrisha N.
Dec 2023: Biobest Group; Closed the acquisition of about 85% of Brazilian biologicals company Biotrop at an enterprise value of BRL 2.8 billion.
Jan 2024: Novonesis; Novozymes and Chr. Hansen completed their merger, forming Novonesis, which includes a portfolio of microbial biosolutions for agriculture.
2025: Syngenta Group; Opened a biostimulants production facility in Orangeburg, South Carolina, U.S., with capacity of up to 16,000 tons per year.
Jul 2025: Syngenta Group; Acquired Intrinsyx Bio, a U.S. start-up developing nutrient use efficiency technologies.
Jul 2025: Pivot Bio; Signed a distribution agreement with Aurora Cooperative (Nebraska and Kansas) for its PROVEN 40 and PROVEN G3 nitrogen-fixing microbial products.
Jan 2026: HGS BioScience; Acquired Pharmgrade, an Idaho-based developer of microbial consortium products.
Jan 2026: Sustainable Agro Solutions; Acquired Ceres Biotics, a producer of microorganism-based biofertilizers and biostimulants with 550 proprietary strains.
Jun 2026: Novonesis; Rovensa Next; Announced an agreement under which Rovensa Next will commercialize Novonesis biosolutions for plant health in the U.S., starting with the 2027 growing season.
Near-term growth will likely concentrate in modular bioreactor lines and closed-system media workflows that shorten validation cycles while preserving batch traceability.
Partnerships between CDMOs and instrumentation vendors should accelerate standard datasets for comparability across sites, improving forecasting models used in capacity planning.
Longer horizon, organoid and microphysiological adoption may reshape segment mix; teams that invest early in assay interoperability and cloud QC hooks are better positioned to capture upside without fragmenting their analytics stack.
Profiles of 110 companies operating in the Microbial Biostimulants Market market, including revenue, employee count, and market positioning where available.
Showing 110 of 110 companies
Company Headquarters: Indianapolis, US Founded: 1989 Workforce: ~21,100 Company Working: Corteva Agriscience develops, manufactures, and markets a wide range of products, including seeds and traits, crop protection, software, and digital solutions, seed treatments, forages, inoculants, vegetation management, pasture management, turf and ornamental, urban pest management, and oil. It is directly present in more than 50 countries and covers all major regions such as North America, Asia-Pacific, Latin America, Europe, and the Middle East & Africa. Corteva Agriscience is a subsidiary of Dow Chemical Company. Hence, the provided financial information is of the Dow Chemical Company.
Indigo Ag is a Flagship Pioneering-founded agricultural technology company. It began in 2013 as a plant-microbiome biotech and grew into one of the most heavily funded agtech ventures in the world. By 2018 it was valued at USD 3.5 billion, and it operated an expansive "five startups in one" model spanning microbial seed treatments, a grain marketplace, logistics, agronomy, and carbon. A sharp market correction followed, with layoffs, exits from grain and transport, and a reported valuation collapse of about 94% in 2023. Under CEO Dean Banks, Indigo then refocused on two franchises. The first is the largest registry-issued U.S. agricultural soil-carbon program, operated by Indigo Carbon PBC. It has issued roughly 2.1 million verified credits and is anchored by a 12-year, 2.85-million-tonne Microsoft offtake. The second is endophyte-based biologicals sold under the biotrinsic® brand with the CLIPS™ applicator, which was carved out in August 2026 as ENAI. Today Indigo is effectively a soil-carbon and sustainability-solutions company with a biologicals affiliate. --- ### Company's own description Indigo describes itself in its 2024–2025 boilerplate as a leader and trusted partner in sustainable agriculture and biological solutions. It says it was established in 2013 and operates in 15 countries. Its stated aim is to turn sustainable on-farm practices into value for farmers, agribusinesses, and corporations (Indigo/GROWMARK release, 12 Nov 2024). An earlier corporate summary listed three core offerings: Carbon, Market+, and biotrinsic. It framed them as integrated across the supply chain and as improving farmer profitability, environmental sustainability, and consumer health (Pubrio company profile, sourced from company LinkedIn). In 2026 releases, Indigo describes itself as among the largest and most mature soil-carbon programs and the only registry-issued agricultural soil-carbon credit program delivering repeated megaton-scale issuances (PR Newswire, 25 Feb 2026). ### Independent characterization As of October 2026, Indigo Ag is best understood as a soil-carbon project developer and environmental-attribute marketplace. It is attached to a legacy agricultural biologicals business that has just been separated into a standalone company, ENAI. The business works as follows. 1. **Carbon (Indigo Carbon PBC / Carbon by Indigo).** Indigo recruits U.S. row-crop farmers to adopt regenerative practices: cover crops, diversified rotations, reduced tillage, and improved nitrogen timing. It measures outcomes using soil sampling, remote sensing, and biogeochemical modeling (DayCent). It then has the results verified by a third party and issued as credits by the Climate Action Reserve (CAR) under the Soil Enrichment Protocol. Finally, it sells the credits to corporate buyers. Farmers are paid on outcomes; a third-party product listing states that 75% of the credit purchase price is returned to farmers. Indigo's revenue is the retained share of credit sales, plus fees for Scope 3 "insetting" programs and MRV services. 2. **Sustainability Solutions / Source / Market+.** These are supply-chain programs for food, beverage, biofuel, and fibre companies. Indigo measures field-level carbon intensity and verifies practice change so that buyers can claim Scope 3 reductions or capture value from clean-fuel tax credits. An example is the Red Trail Energy collaboration on low-CI ethanol feedstock. 3. **Biologicals (biotrinsic® + CLIPS™; transferring to ENAI).** These are microbial seed and foliar treatments: biostimulants, biofungicides, and bionematicides. They are sold through ag retailers, cooperatives such as GROWMARK, and distributors in the Americas, Türkiye, and elsewhere. CLIPS is a hands-free powder applicator that sits in the seed box and makes adoption easier. ### Value-chain position, customers, end-markets Indigo sits at the farm-gate interface. Upstream, it supplies inputs (biologicals) to growers and retailers. Downstream, it aggregates and certifies environmental outcomes from those growers for corporate buyers. It serves three customer groups: **growers:** (U.S. corn, soy, wheat, cotton, and other row crops; the carbon program spans 28 states and more than 8 million enrolled acres); **agribusiness channel partners:** (retail cooperatives, seed companies, distributors); **corporate buyers:** (tech companies, financial institutions, CPG/food, apparel, and biofuel producers). The main end-markets are the voluntary carbon market (VCM), corporate Scope 3 programs, U.S. clean-fuel incentive markets (45Z), and the global agricultural biologicals market.
BASF is the world's largest chemical company by sales, built on the Verbund principle of physically and energetically integrated production sites that turn a handful of feedstocks into thousands of products. Since September 2024 it has run under the "Winning Ways" strategy, which splits the portfolio into four core segments (Chemicals, Materials, Industrial Solutions, Nutrition & Care) that stay integrated, and standalone businesses (Agricultural Solutions, Battery Materials, Environmental Catalyst and Metal Solutions, and the now-divested Coatings) that are being monetized or prepared for capital-market options. In 2025 it generated €59.7 billion in sales and €6.6 billion in EBITDA before special items, a cyclical trough. In 2026 it closed the €7.7 billion Coatings transaction, started up its €-multi-billion Zhanjiang Verbund site, raised earnings guidance, and approached Evonik about a takeover. The investment debate is whether structural cost cuts and portfolio proceeds can restore returns above the cost of capital. --- **The company's own description.** BASF describes its purpose with the line "we create chemistry for a sustainable future" (BASF news release boilerplate, 2026) and states its ambition to be the preferred chemical company for enabling customers' green transformation. It reports around 108,000 employees, customers in nearly every sector and almost every country, and sales of around €60 billion in 2025. The portfolio is described as four core segments plus standalone businesses bundled in Surface Technologies and Agricultural Solutions. **Independent characterization.** BASF is best understood as three businesses under one roof: 1. **An integrated commodity and intermediates engine** (Chemicals, the Monomers half of Materials). This is a steam-cracker-to-derivatives chain selling ethylene and propylene derivatives, isocyanates, polyamide precursors and intermediates on spread economics. Earnings are driven by feedstock and energy costs, operating rates and regional supply-demand. It is the most capital-intensive part of the group and the main source of the 2023–2025 earnings decline: Chemicals EBITDA before special items fell from €1,342 million in 2024 to €853 million in 2025 (Factsheet FY2025). 2. **Formulated and performance products** (Performance Materials, Industrial Solutions, Nutrition & Care). These sell on specification and performance to automotive, construction, packaging, consumer goods, pharma and nutrition customers. Margins are steadier but have come under pressure from Asian competition and, in Care Chemicals, from consumer trading-down to private-label products (Factsheet FY2025 commentary). 3. **Standalone franchises** with different industry logic: Agricultural Solutions (crop protection, seeds and traits, digital farming), ECMS (emissions catalysts plus precious-metal trading and recycling) and Battery Materials. Agricultural Solutions is the group's highest-margin segment at 21.7% EBITDA margin before special items in FY2025 and the largest single earnings contributor at €2,081 million. **Revenue model.** Revenue is almost entirely product sales under supply contracts and spot transactions. There is no subscription model of consequence; digital farming (xarvio) and licensing of process technology and catalysts are small. Seeds and traits include royalty and licensing income within Agricultural Solutions, not separately disclosed. Precious-metal trading inflates ECMS sales (€7,978 million in FY2025) with pass-through metal value, which is why BASF quotes group margins both including and excluding metals (12.3% excluding metals in FY2025 per the CFO on the February 27, 2026 call, versus 11.0% reported). **Value chain position.** Upstream to midstream in petrochemicals with captive crackers at Ludwigshafen, Antwerp, Port Arthur (joint venture with TotalEnergies), Nanjing (joint venture with Sinopec) and Zhanjiang; midstream to downstream in engineering plastics, polyurethane systems, dispersions, additives, surfactants and vitamins; branded and channel-driven in agriculture. BASF exited upstream oil and gas operations when Wintershall Dea's E&P business was transferred to Harbour Energy in September 2024. **Customers and end-markets.** BASF serves industrial customers in chemicals and plastics, transportation, construction, consumer goods, agriculture, electronics, energy and resources, and health and nutrition. Intersegment transfers are large (Chemicals transferred €3,432 million internally in FY2025 on €10,055 million of third-party sales), which shows how much of the upstream output feeds BASF's own downstream chains.
Bayer is a German life-science group with three businesses: Crop Science, Pharmaceuticals and Consumer Health. It is the world's largest combined seed, trait and crop-protection supplier, a mid-sized prescription-drug maker, and a top-five self-care company. Fiscal 2025 sales were EUR 45.6 billion. The 2018 purchase of Monsanto brought leading corn and soybean genetics but also glyphosate and PCB litigation, which has consumed well over EUR 10 billion in settlements and produced net losses in 2023, 2024 and 2025. Under CEO Bill Anderson the company has cut management layers, held the dividend at the legal minimum, and concentrated on four priorities: rebuilding the pharma pipeline, containing litigation, reducing debt and improving crop profitability. In 2026 a 7–2 U.S. Supreme Court ruling on federal pre-emption and a proposed USD 7.25 billion class settlement moved the litigation closer to resolution, though the settlement still awaits final court approval. --- **Company's own description.** Bayer describes itself as a global enterprise with core competencies in the life-science fields of health care and nutrition, operating under the mission "Health for all, Hunger for none" (Annual Report 2025; press boilerplate 2026). Bayer AG is a holding company; operations sit in subsidiaries worldwide. In fiscal 2025 the Group had about 88,000 employees, sales of EUR 45.6 billion and R&D expenses of EUR 5.8 billion. **Independent characterisation.** Bayer is best understood as three distinct businesses sharing a balance sheet, a brand and a legal liability. Crop Science (47 percent of FY2025 sales) is an input supplier to farmers. It earns money from proprietary seed and biotech traits, from chemical and biological crop protection, and to a small extent from digital farming subscriptions. Seed and trait revenue carries royalty-like economics: Bayer licenses traits to other seed companies, and two licensing settlements with Corteva lifted results in Q4 2025 and Q1 2026. The business is strongly seasonal, with Northern Hemisphere sales concentrated in the first half and Latin American sales in the second. Pharmaceuticals (39 percent of sales) discovers, develops and sells prescription medicines, concentrated in cardiovascular and renal disease, oncology, women's health and ophthalmology, plus a radiology unit selling contrast agents and injector hardware. Revenue is almost entirely product sales, with some licence income (for example U.S. Xarelto royalties from Johnson & Johnson, and Eylea outside the United States under a collaboration with Regeneron). The division is in the middle of a patent transition: Xarelto and Eylea are declining while Nubeqa and Kerendia are growing quickly. Consumer Health (13 percent of sales) sells non-prescription brands through pharmacies, mass retail and e-commerce. It is a branded consumer-goods model with stable margins and low capital intensity. **Revenue model mix.** Bayer does not disclose a product/service/licensing split. On the evidence of the Annual Report 2025, the large majority of revenue is product sales; licensing income is embedded in Crop Science seed and trait lines and in Pharmaceuticals; subscription revenue (Climate FieldView, radiology software) is immaterial at Group level. An exact percentage split is not publicly disclosed. **Value-chain position.** Bayer is a research-based originator and manufacturer. It owns discovery, development, active-ingredient and finished-product manufacturing, and commercial organisations, and sells through distributors, retailers, wholesalers, hospitals and pharmacies rather than directly to end users in most markets. **Customers and end markets.** Farmers, agricultural retailers and distributors, and seed licensees (Crop Science); wholesalers, hospitals, physicians, pharmacy chains, governments and payers (Pharmaceuticals); pharmacies, supermarkets, drugstores and online retailers (Consumer Health).
4 interactive charts drawn from the Microbial Biostimulants Market dataset — market size, regional splits and each segment breakdown. Open one to read its full data table and download it.
Global Microbial Biostimulants Market By Application Method
Global Microbial Biostimulants Market By Crop Type
Global Microbial Biostimulants Market By Microorganism Type
Global Microbial Biostimulants Market By Region
Powering the world's best teams.
From next-gen startups to established enterprises.
Trusted by forward-thinking businesses
for data-driven intelligence
Co-Founder, Mojave Rail Fabrication Limited
This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job.
Manager, JavolVision
Thanks, I am so happy that we worked together. Maybe we still can work together in the future.
Sales Operations & Pricing Manager, Intel
Thanks. It's been a pleasure working with you, please use me as reference with any other Intel employees.
Sales Leader, Bamberg
We bought your "2025 report" in 2020. Everything is fine and very good.
Account and Business Manager, EFS-Holland BV
Thanks for sending the report it gives us a good global view of the Betaïne market.
Senior Retail Manager, LG Chem
We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.
Management Consultant, Level 21
I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.
Group Product Manager HVAC & Fire Protection GMA, Rockwool
I have been reading the first document or the study, the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!
R&D Director, Seojin
Thanks for your great support. Appreciate it. Well received report. It helps us to understand market well. We're planning other area of survey in the future, let's keep in touch.
Strategy & Business Development Director, Dogan Holding
We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.
Historical performance and future projections (2020–2030, USD Billion)
Market Size (USD Million)
